Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer | MicrobiomeTrials← Back to trialsNCT07374796
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer
RecruitingOBSERVATIONAL
Trial Details
Start: 2026-12Est. Completion: 2033-01
Enrollment target: 450 participants Locations- University of Maryland Baltimore Washington Medical Center, Glen Burnie, Maryland, United States
Other microbiome trials you might be interested in
Metastatic Breast Cancer
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with met…
Duarte, United StatesEst. completion Sep 30, 2030
Breast Cancer Metastatic
The study will be conducted as an open-label, single-center, Phase II clinical study, with a planned enrollment of 86 pa…
Shanghai, ChinaEst. completion Nov 11, 2026